Affibody AB
Voltavägen 13, Floor 5
Bromma
SE-168 69
Tel: 46-0-8-598-83800
Fax: 46-0-8-598-83801
Website: http://www.affibody.com/
Email: contact@affibody.com
36 articles with Affibody AB
-
Acelyrin, Affibody AB and Inmagene Biopharmaceuticals presented positive Phase II data for izokibep in psoriatic arthritis, while Aurinia's Lupkynis hit post-hoc treatment targets in lupus nephritis.
-
ACELYRIN, INC., Affibody AB and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 European Alliance of Associations for Rheumatology Congress
6/3/2022
The randomized double-blind, placebo-controlled, Phase 2 clinical trial evaluated the safety and efficacy of izokibep dosed 80 mg every two weeks or 40 mg Q2W, versus placebo Q2W, in adult patients with active PsA.
-
ACELYRIN, INC., Affibody AB, and Inmagene Bio Announce Positive Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis
5/3/2022
ACELYRIN, INC., Affibody AB, and Inmagene Biopharmaceuticals Co., Ltd., announced that a 16-week, global, Phase 2 clinical trial of izokibep in 135 patients with psoriatic arthritis met its primary endpoint of ACR50.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Biopharma and life sciences companies from across the globe provide updates. Belgium-based Galapagos NV won European approval for Jyseleca for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
-
Los Angeles-based ACELYRIN, Inc. announced a quarter-million dollars in Series B financing Tuesday morning, along with a splashy licensing deal.
-
BioSpace Global Roundup, March 11
3/11/2021
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
Clinical Catch-Up: February 8-12
2/15/2021
It was a busy week for clinical trial announcements and news. Here’s a look. -
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
-
BioSpace Global Roundup, Nov. 12
11/12/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
BioSpace Global Roundup, June 18
6/18/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations. -
BioSpace Global Roundup, May 14
5/14/2020
Biopharma and life sciences companies from across the globe provide updates on their pipeline and business. -
BioSpace Global Roundup, May 7
5/7/2020
Pharma and life sciences companies from across the globe provide updates on their business and pipelines. -
BioSpace Global Roundup, Sept. 26
9/26/2019
Companies from across the globe share updates on their business and pipelines. -
BioSpace Global Roundup, July 18
7/18/2019
Pharma and biotech companies from across the globe provide updates on their pipelines and corporate strategy. -
Alexion and Affibody Announce Partnership to Co-Develop Anti-FcRn Affibody® Molecule
3/20/2019
Affibody to receive $25 million upfront payment with potential for additional milestone-dependent and royalty payments, and option for U.S. co-promote
-
Alexion Pharmaceuticals announced two big collaboration partnerships today. First, Alexion, headquartered in Boston, and Affibody AB, located in Solna, Sweden, signed a partnership deal to co-develop ABY-039 for Immunoglobulin G (IgG)-mediated autoimmune diseases.
-
Lots of interesting biotech news from Asia, Europe and elsewhere was reported this week. From tapeworms to using a breathalyzer test in lung cancer diagnostics, the global biotech industry is exploding with ideas.
-
Affibody Announces Initial Results From Phase I Psoriasis Study Of ABY-035
5/4/2016